NCT01701375View on ClinicalTrials.gov

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Relapsed Acute LeukemiaRefractory Acute LeukemiaHigh-Risk Myelodysplasia
Interventions
DRUG

PD 0332991

• PD 0332991 will be given orally days 1,2,3

Trial Locations (2)

10065

Weill Cornell Medical Center, New York

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01701375 - A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia | Biotech Hunter | Biotech Hunter